Host circulating biomarkers for immune-checkpoint inhibitors: single-agent and combinations

Future Oncol. 2020 Aug;16(23):1665-1668. doi: 10.2217/fon-2020-0182. Epub 2020 May 18.

Authors

Mariona Riudavets¹, Edouard Auclin², Laura Mezquita³

Affiliations

¹ Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB) Medicine Department, Barcelona, 08041, Spain.
² Medical Oncology Department, Hôpital Européen Georges Pompidou, Paris, 75015, France.
³ Medical Oncology Department, Hospital Clinic, Barcelona, 08036, Spain.

PMID: 32422071
DOI: 10.2217/fon-2020-0182

No abstract available

Keywords: circulating biomarkers; combination therapies; host-related biomarkers; immune-checkpoint inhibitors; solid tumors.

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers, Tumor / blood*
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Neoplasms / blood*
Neoplasms / drug therapy
Neoplasms / immunology
Prognosis

Substances

Biomarkers, Tumor
Immune Checkpoint Inhibitors